OncoMatch/Clinical Trials/NCT06581406
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Is NCT06581406 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including RP2 and Ipilimumab for metastatic uveal melanoma.
Treatment: RP2 · Ipilimumab · Nivolumab — The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Melanoma
Disease stage
Metastatic disease required
metastatic Uveal melanoma not amenable to surgical resection; at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for a lymph node [LN])
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Any exposure to immune checkpoint inhibitor (ICIs) since the time of first being diagnosed with uveal melanoma
Cannot have received: oncolytic virus
Prior treatment with an oncolytic virus
Cannot have received: systemic anticancer therapy
Systemic anticancer therapy or prior radiotherapy within 2 weeks of the first dose
Cannot have received: investigational agent
Has received Investigation agent within 4 weeks or 5 half-lives (whichever longer) prior to the first dose
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
LDH ≤ 2 × upper limit of normal (ULN); adequate hepatic function
LDH ≤ 2 × upper limit of normal (ULN). Has adequate hematologic, hepatic and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth Research Insisute · Scottsdale, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- The Angeles Clinic and Research Institute · Los Angeles, California
- University of California Los Angeles · Los Angeles, California
- Stanford Cancer Institute · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06581406 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, oncolytic virus, systemic anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages